Evidence map›Paper›PMID 41757741›Full record

ArticleFuture oncology (London, England)2026

Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the US.

Tara Graff, Savreet Bains Chawla, Monika Jun, Nicole Heaps, Abualbishr Alshreef, David Tybor, Donald C Moore, Nadine Zawadzki, Kathryn Spurrier, Jason Shafrin

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Tara GraffHematology/Oncology, Mission Cancer + Blood, Des Moines, IA, USA.
Savreet Bains ChawlaCenter for Outcomes Research, Real World Evidence and Epidemiology, Genmab, Plainsboro, NJ, USA.
Monika JunCenter for Outcomes Research, Real World Evidence and Epidemiology, Genmab, Plainsboro, NJ, USA.
Nicole HeapsCenter for Outcomes Research, Real World Evidence and Epidemiology, Genmab, Plainsboro, NJ, USA.
Abualbishr AlshreefOncology Value and Evidence, AbbVie, Chicago, IL, USA.
David TyborOncology Value and Evidence, AbbVie, Chicago, IL, USA.
Donald C MooreOncology, Atrium Health Levine Cancer Institute, Charlotte, NC, USA.
Nadine ZawadzkiCenter for Healthcare Economics and Policy, FTI Consulting, Los Angeles, CA, USA.
Kathryn SpurrierCenter for Healthcare Economics and Policy, FTI Consulting, Washington, DC, USA.
Jason ShafrinCenter for Healthcare Economics and Policy, FTI Consulting, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo quantify the time- and cost-savings to US oncology practices from using a single bispecific antibody (bsAb) for both relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) compared with using two separate single-indication therapies. MATERIALS &

methodsThe study conducted a national survey of clinicians (oncologists, pharmacists, nurses/physician assistants) treating non-Hodgkin lymphoma (NHL) patients in the US to quantify the impact of operational efficiencies identified through formative qualitative interviews with oncology staff. Quantitative analysis estimated time-savings based on survey data, assuming one new prescription per patient per year and 12 (DLBCL) and 15 (FL) administration visits per patient per year. Time-savings were combined with staff wage rates to estimate cost-savings.

resultsAmong n = 105 respondents, drivers of operational efficiencies included onboarding, coordinating insurance and financial aid, and medication preparation. For a hypothetical community practice treating 100 bsAb-eligible patients (61% DLBCL, 39% FL), total time-savings were 3110 h in the first year of adoption, resulting in total monetized time-savings of $278,013. For a hypothetical academic practice, monetized time-savings were $963,074 in the first year of adoption.

conclusionsUsing a single bsAb to treat R/R DLBCL and FL is predicted to lead to considerable time- and cost-savings for oncology practices.

Indexed as

Antibodies, BispecificLymphoma, FollicularLymphoma, Large B-Cell, DiffuseCost-Benefit AnalysisCost SavingsHumansUnited StatesAntibodies, Bispecificbispecific antibodiesDiffuse large B-cell lymphomafollicular lymphomanon-Hodgkin lymphomaoncology practiceoperational efficiencypractice costs

Identifiers

PMID41757741
PMCPMC13048542

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.